Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes

References

• Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16(7):896–913. doi:10.1093/neuonc/nou087.
   PubMed Web of Science ®Google Scholar
• Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402–2409. doi:10.1200/JCO.2017.73.0119.
   PubMed Web of Science ®Google Scholar
• Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma—an update. Crit Rev Oncol Hematol. 2016;99:389–408. doi:10.1016/j.critrevonc.2016.01.018.
   PubMed Web of Science ®Google Scholar
• Keskin DB, Anandappa AJ, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–239. doi:10.1038/s41586-018-0792-9.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–161. doi:10.1056/NEJMoa1716435.
   PubMed Web of Science ®Google Scholar
• Kamath SD, Kumthekar PU. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Front Oncol. 2018;8:414. doi:10.3389/fonc.2018.00414.
   PubMed Web of Science ®Google Scholar
• Simonelli M, Persico P, Perrino M, et al. Checkpoint inhibitors as treatment for malignant gliomas: “a long way to the top”. Cancer Treat Rev. 2018;69:121–131. doi:10.1016/j.ctrv.2018.06.016.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system. Science. 2016;353(6301):766–771. doi:10.1126/science.aag2638.
   PubMed Web of Science ®Google Scholar
• Brown CE, Starr R, Aguilar B, et al. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine–redirected T cells. Clin Cancer Res. 2012;18(8):2199–2209. doi:10.1158/1078-0432.CCR-11-1669.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Johnson LA, Davis JL, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 2012;23(10):1043–1053. doi:10.1089/hum.2012.041.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474–485. doi:10.1158/1078-0432.CCR-09-1322.
   PubMed Web of Science ®Google Scholar
• Miao H, Gale NW, Guo H, et al. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene. 2015;34(5):558–567. doi:10.1038/onc.2013.590.
   PubMed Web of Science ®Google Scholar
• Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M + diffuse midline gliomas. Nat Med. 2018;24(5):572–579. doi:10.1038/s41591-018-0006-x.
   PubMed Web of Science ®Google Scholar
• Golinelli G, Grisendi G, Prapa M, et al. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther. 2020;27(7-8):558–570. doi:10.1038/s41417-018-0062-x.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–2574. doi:10.1158/1078-0432.CCR-18-0432.
   PubMed Web of Science ®Google Scholar
• Maude S, Grupp S, Pulsipher M, Rives S, Myers G, Verneris M, et al. Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). In: Haematologica (Vol. 102, pp. 197–198). Pavia, Italy: Ferrata Storti Foundation; 2017.
   Google Scholar
• Neelapu SS. CAR-T efficacy: is conditioning the key? Blood. J Am Soc Hematol. 2019;133(17):1799–1800. doi:10.1182/blood-2019-03-900928.
   Google Scholar
• Negi N, Das BK. CNS: Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ. Int Rev Immunol. 2018;37(1):57–68. doi:10.1080/08830185.2017.1357719.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337–341. doi:10.1038/nature14432.
   PubMed Web of Science ®Google Scholar
• Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol. 2006;80(4):797–801. doi:10.1189/jlb.0306176.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623–635. doi:10.1038/nri3265.
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Desai AS, Linette GP, June CH, O’Rourke DM. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018;20(11):1429–1438. doi:10.1093/neuonc/noy032.
   PubMed Web of Science ®Google Scholar
• Patterson JD, Henson JC, Breese RO, Bielamowicz KJ, Rodriguez A. CAR T cell therapy for pediatric brain tumors. Front Oncol. 2020;10:1582. doi:10.3389/fonc.2020.01582.
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110(10):4009–4014. doi:10.1073/pnas.1219747110.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. doi:10.1126/scitranslmed.aaa0984.
   PubMed Web of Science ®Google Scholar
• Hao C, Parney IF, Roa WH, Turner J, Petruk KC, Ramsay DA. Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol. 2002;103(2):171–178. doi:10.1007/s004010100448.
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Idema AJ, Bol KF, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009;11(4):394–402. doi:10.1215/15228517-2008-104.
   PubMed Web of Science ®Google Scholar
• Zhu C, Mustafa D, Zheng P-p, et al. Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression. Neuro-oncology. 2017;19(5):now251–59. doi:10.1093/neuonc/now251.
   Web of Science ®Google Scholar
• Mirzaei R, Sarkar S, Yong VW. T cell exhaustion in glioblastoma: intricacies of immune checkpoints. Trends Immunol. 2017;38(2):104–115. doi:10.1016/j.it.2016.11.005.
   PubMed Web of Science ®Google Scholar
• Wei J, Wu A, Kong L-Y, et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011;6(1):e16195. doi:10.1371/journal.pone.0016195.
   PubMed Web of Science ®Google Scholar
• Howie D, Waldmann H, Cobbold S. Nutrient sensing via mTOR in T cells maintains a tolerogenic microenvironment. Front Immunol. 2014;5:409. doi:10.3389/fimmu.2014.00409.
   PubMed Web of Science ®Google Scholar
• Haberthur K, Brennan K, Hoglund V, et al. NKG2D ligand expression in pediatric brain tumors. Cancer Biol Ther. 2016;17(12):1253–1265. doi:10.1080/15384047.2016.1250047.
   PubMed Web of Science ®Google Scholar
• Lieberman NA, DeGolier K, Kovar HM, et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 2019;21(1):83–94. doi:10.1093/neuonc/noy145.
   PubMed Web of Science ®Google Scholar
• Pham CD, Flores C, Yang C, et al. Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma. Clin Cancer Res. 2016;22(3):582–595. doi:10.1158/1078-0432.CCR-15-0713.
   PubMed Web of Science ®Google Scholar
• Griesinger AM, Josephson RJ, Donson AM, et al. Interleukin-6/STAT3 pathway signaling drives an inflammatory phenotype in Group A ependymoma. Cancer Immunol Res. 2015;3(10):1165–1174. doi:10.1158/2326-6066.CIR-15-0061.
   PubMed Web of Science ®Google Scholar
• Lu J-Q, Wilson BA, Yong VW, Pugh J, Mehta V. Immune cell infiltrates in atypical teratoid/rhabdoid tumors. Can J Neurol Sci. 2012;39(5):605–612. doi:10.1017/S031716710001533X.
   PubMed Web of Science ®Google Scholar
• Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H. Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy. Front Immunol. 2019;9:3062. doi:10.3389/fimmu.2018.03062.
   PubMed Web of Science ®Google Scholar
• Ratnam NM, Gilbert MR, Giles AJ. Immunotherapy in CNS cancers: the role of immune cell trafficking. Neuro Oncol. 2019;21(1):37–46. doi:10.1093/neuonc/noy084.
   PubMed Web of Science ®Google Scholar
• Van Tellingen O, Yetkin-Arik B, De Gooijer M, Wesseling P, Wurdinger T, De Vries H. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12. doi:10.1016/j.drup.2015.02.002.
   PubMed Web of Science ®Google Scholar
• Stine CA, Munson JM. Convection-enhanced delivery: connection to and impact of interstitial fluid flow. Front Oncol. 2019;9:966. doi:10.3389/fonc.2019.00966.
   PubMed Web of Science ®Google Scholar
• Keu KV, Witney TH, Yaghoubi S, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017;9(373):eaag2196. doi:10.1126/scitranslmed.aag2196.
   PubMed Web of Science ®Google Scholar
• Goff SL, Morgan RA, Yang JC, et al. Pilot trial of adoptive transfer of chimeric antigen receptor transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019;42(4):126–135. ). doi:10.1097/CJI.0000000000000260.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123–e7. doi:10.1016/j.bbmt.2018.12.756.
   PubMedGoogle Scholar
• Morgan RA. Faster, cheaper, safer, T cell engineering. J Immunother. 2013;36(1):1–2. doi:10.1097/CJI.0b013e3182791257.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062–4072. doi:10.1158/1078-0432.CCR-15-0428.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–2569. doi:10.1056/NEJMoa1610497.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094–1101. doi:10.1001/jamaoncol.2017.0184.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934–941. doi:10.1038/s41586-022-04489-4.
   PubMed Web of Science ®Google Scholar
• Tang X, Liu F, Liu Z, et al. Bioactivity and safety of B7‐H3‐targeted chimeric antigen receptor T cells against anaplastic meningioma. Clin Transl Immunol. 2020;9(6):e1137. doi:10.1002/cti2.1137.
   PubMed Web of Science ®Google Scholar
• Yagita M, Huang C, Umehara H, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14(5):922–930. doi:10.1038/sj.leu.2401769.
   PubMed Web of Science ®Google Scholar
• Kim K, Gwak H-S, Han N, et al. Chimeric antigen receptor T cells with modified interleukin-13 preferentially recognize IL13Rα2 and suppress malignant glioma: a preclinical study. Front Immunol. 2021;12:715000. doi:10.3389/fimmu.2021.715000.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, et al. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. J Immunother Cancer. 2015;3(S2):1. doi:10.1186/2051-1426-3-S2-O11.
   PubMedGoogle Scholar
• Donovan LK, Delaidelli A, Joseph SK, et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020;26(5):720–731. doi:10.1038/s41591-020-0827-2.
   PubMed Web of Science ®Google Scholar
• Portnow J, Wang D, Blanchard MS, et al. Systemic anti–PD-1 immunotherapy results in PD-1 blockade on T cells in the cerebrospinal fluid. JAMA Oncol. 2020;6(12):1947–1951. doi:10.1001/jamaoncol.2020.4508.
   PubMed Web of Science ®Google Scholar
• Vitanza NA, Johnson AJ, Wilson AL, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021;27(9):1544–1552. doi:10.1038/s41591-021-01404-8.
   PubMed Web of Science ®Google Scholar
• Bagley S, Desai A, Binder Z, et al. RBTT-12. A phase I study of EGFRvIII-directed CAR T cells combined with PD-1 inhibition in patients with newly, diagnosed, MGMT-unmethylated glioblastoma: trial in progress. Neuro-oncology. 2019;21(Supplement_6):vi221–vi221. doi:10.1093/neuonc/noz175.923.
   Google Scholar
• Sague SL, Tato C, Puré E, Hunter CA. The regulation and activation of CD44 by natural killer (NK) cells and its role in the production of IFN-γ. J Interferon Cytokine Res. 2004;24(5):301–309. doi:10.1089/107999004323065093.
   PubMed Web of Science ®Google Scholar
• Springuel L, Lonez C, Alexandre B, et al. Chimeric antigen receptor-T cells for targeting solid tumors: current challenges and existing strategies. BioDrugs. 2019;33(5):515–537. doi:10.1007/s40259-019-00368-z.
   PubMed Web of Science ®Google Scholar
• Cruz FM, Colbert JD, Merino E, Kriegsman BA, Rock KL. The biology and underlying mechanisms of cross-presentation of exogenous antigens on MHC-I molecules. Annu Rev Immunol. 2017;35(1):149–176. doi:10.1146/annurev-immunol-041015-055254.
   PubMed Web of Science ®Google Scholar
• Pearce CM, Chrostek MR, Fellows EG, et al. Immunotherapy and checkpoint inhibitors for gliomas. Neuroimmunol Neuroinflammation. 2018;5(11):47. doi:10.20517/2347-8659.2018.46.
   Google Scholar
• You F, Jiang L, Zhang B, et al. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci. 2016;59(4):386–397. doi:10.1007/s11427-016-5024-7.
   PubMed Web of Science ®Google Scholar
• Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 2021;28(3-4):321–334. doi:10.1038/s41417-020-00221-4.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Miyagaki T, Kamijo H, et al. CD147-cyclophilin A interactions promote proliferation and survival of cutaneous T-cell lymphoma. Int J Mol Sci. 2021;22(15):7889. doi:10.3390/ijms22157889.
   PubMed Web of Science ®Google Scholar
• Land CA, Musich PR, Haydar D, Krenciute G, Xie Q. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. J Transl Med. 2020;18(1):1–13. doi:10.1186/s12967-020-02598-0.
   PubMed Web of Science ®Google Scholar
• Thomas P, Galopin N, Bonérandi E, Clémenceau B, Fougeray S, Birklé S. CAR T cell therapy’s potential for pediatric brain tumors. Cancers. 2021;13(21):5445. doi:10.3390/cancers13215445.
   PubMed Web of Science ®Google Scholar
• Badie B, Barish ME, Chaudhry A, et al. A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392). J Clin Oncol. 2021;39(15_suppl):TPS2662–TPS2662. doi:10.1200/JCO.2021.39.15_suppl.TPS2662.
   Web of Science ®Google Scholar
• Lin Q, Ba T, Ho J, et al. First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: A preliminary report of three cases at the starting dose. Front Oncol. 2021;11:2238. doi:10.3389/fonc.2021.694941.
   Web of Science ®Google Scholar
• Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997;57(18):4130–4140.
   PubMed Web of Science ®Google Scholar
• Mineo J-F, Bordron A, Baroncini M, et al. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol. 2007;85(3):281–287. doi:10.1007/s11060-007-9424-1.
   PubMed Web of Science ®Google Scholar
• Rutkowska A, Stoczyńska-Fidelus E, Janik K, Włodarczyk A, Rieske P. EGFRvIII: an oncogene with ambiguous role. J Oncol. 2019;2019:1092587. doi:10.1155/2019/1092587.
   PubMed Web of Science ®Google Scholar
• Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5(7):953–962.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851. doi:10.1038/mt.2010.24.
   PubMed Web of Science ®Google Scholar
• Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res. 2019;38(1):1–13. doi:10.1186/s13046-019-1085-3.
   PubMed Web of Science ®Google Scholar
• Brown CE, Aguilar B, Starr R, et al. Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018;26(1):31–44. doi:10.1016/j.ymthe.2017.10.002.
   PubMed Web of Science ®Google Scholar
• Karimi-Shahri M, Khorramdel M, Zarei S, Attarian F, Hashemian P, Javid H. Glioblastoma, an opportunity T cell trafficking could bring for the treatment. Mol Biol Rep. 2022:1–13. doi:10.1007/s11033-022-07510-1.
   PubMed Web of Science ®Google Scholar
• Yi Z, Prinzing BL, Cao F, Gottschalk S, Krenciute G. Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma. Mol Ther Methods Clin Dev. 2018;9:70–80. doi:10.1016/j.omtm.2018.01.009.
   PubMed Web of Science ®Google Scholar
• Ponterio E, De Maria R, Haas TL. Identification of targets to redirect CAR T cells in glioblastoma and colorectal cancer: an arduous venture. Front Immunol. 2020;11:2339. doi:10.3389/fimmu.2020.565631.
   Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–1271. doi:10.1084/jem.20052494.
   PubMed Web of Science ®Google Scholar
• Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007;204(1):49–55. doi:10.1084/jem.20062056.
   PubMed Web of Science ®Google Scholar
• Jin L, Ge H, Long Y, et al. CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol. 2018;20(1):55–65. doi:10.1093/neuonc/nox116.
   PubMed Web of Science ®Google Scholar
• Flynn JP, O'Hara MH, Gandhi SJ. Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (ie, CART). Transl Lung Cancer Res. 2017;6(2):159–168. doi:10.21037/tlcr.2017.03.07.
   PubMed Web of Science ®Google Scholar
• Minn I, Rowe SP, Pomper MG. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. Lancet Oncol. 2019;20(8):e443–e51. doi:10.1016/S1470-2045(19)30461-9.
   PubMed Web of Science ®Google Scholar
• Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180(5):3132–3139. doi:10.4049/jimmunol.180.5.3132.
   PubMed Web of Science ®Google Scholar
• Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181(5):3099–3107. doi:10.4049/jimmunol.181.5.3099.
   PubMed Web of Science ®Google Scholar
• Portella L, Scala S. Ionizing radiation effects on the tumor microenvironment. Seminars in Oncology. 2019;46(3):254–260. doi:10.1053/j.seminoncol.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Arvanitis CD, Ferraro GB, Jain RK. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26–41. doi:10.1038/s41568-019-0205-x.
   PubMed Web of Science ®Google Scholar
• DeSelm C, Palomba ML, Yahalom J, et al. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther. 2018;26(11):2542–2552. doi:10.1016/j.ymthe.2018.09.008.
   PubMed Web of Science ®Google Scholar
• Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018;78(4):1031–1043. doi:10.1158/0008-5472.CAN-17-1788.
   PubMed Web of Science ®Google Scholar
• Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711–723. e4. doi:10.1016/j.ccell.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Smith TT, Moffett HF, Stephan SB, et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest. 2017;127(6):2176–2191. doi:10.1172/JCI87624.
   PubMed Web of Science ®Google Scholar
• Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862–870. doi:10.1016/j.ijrobp.2003.09.012.
   PubMed Web of Science ®Google Scholar
• Lutsiak MC, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4 + 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105(7):2862–2868. doi:10.1182/blood-2004-06-2410.
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nat Clin Pract Oncol. 2006;3(12):668–681. doi:10.1038/ncponc0666.
   PubMedGoogle Scholar
• Xu J, Wang Y, Shi J, Liu J, Li Q, Chen L. Combination therapy: a feasibility strategy for CAR‑T cell therapy in the treatment of solid tumors. Oncol Lett. 2018;16(2):2063–2070. doi:10.3892/ol.2018.8946.
   PubMed Web of Science ®Google Scholar
• Geyer MB, Rivière I, Sénéchal B, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 2019;4(9):e122627. doi:10.1172/jci.insight.122627.
   PubMed Web of Science ®Google Scholar
• Abril-Rodriguez G, Ribas A. SnapShot: immune checkpoint inhibitors. Cancer Cell. 2017;31(6):848–8e1. doi:10.1016/j.ccell.2017.05.010.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Yang K, Shrestha S, Zeng H, et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity. 2013;39(6):1043–1056. doi:10.1016/j.immuni.2013.09.015.
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20(20):5290–5301. doi:10.1158/1078-0432.CCR-14-0514.
   PubMed Web of Science ®Google Scholar
• Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8(53):91779–91794. doi:10.18632/oncotarget.21586.
   PubMedGoogle Scholar
• Mantica M, Pritchard A, Lieberman F, Drappatz J. Retrospective study of nivolumab for patients with recurrent high grade gliomas. J Neurooncol. 2018;139(3):625–631. doi:10.1007/s11060-018-2907-4.
   PubMed Web of Science ®Google Scholar
• Romani M, Pistillo MP, Carosio R, Morabito A, Banelli B. Immune checkpoints and innovative therapies in glioblastoma. Front Oncol. 2018;8:464. doi:10.3389/fonc.2018.00464.
   PubMed Web of Science ®Google Scholar
• Desai K, Hubben A, Ahluwalia M. The role of checkpoint inhibitors in glioblastoma. Target Oncol. 2019;14(4):375–394. doi:10.1007/s11523-019-00655-3.
   PubMed Web of Science ®Google Scholar
• Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–339.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• Shen SH, Woroniecka K, Barbour AB, Fecci PE, Sanchez-Perez L, Sampson JH. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020;20(6):579–591. doi:10.1080/14712598.2020.1727436.
   PubMed Web of Science ®Google Scholar
• Lawler SE, Speranza M-C, Cho C-F, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3(6):841–849. doi:10.1001/jamaoncol.2016.2064.
   PubMed Web of Science ®Google Scholar
• Iorgulescu JB, Reardon DA, Chiocca EA, Wu CJ. Immunotherapy for glioblastoma: going viral. Nat Med. 2018;24(8):1094–1096. doi:10.1038/s41591-018-0142-3.
   PubMed Web of Science ®Google Scholar
• Martikainen M, Essand M. Virus-based immunotherapy of glioblastoma. Cancers. 2019;11(2):186. doi:10.3390/cancers11020186.
   Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788. doi:10.1200/JCO.2014.58.3377.
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Cutting edge: type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol. 2005;174(8):4465–4469. doi:10.4049/jimmunol.174.8.4465.
   PubMed Web of Science ®Google Scholar
• Spaapen RM, Leung MY, Fuertes MB, et al. Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature. J Immunol. 2014;193(8):4254–4260. doi:10.4049/jimmunol.1401109.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Koch MA, Pepper M, Campbell DJ. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med. 2014;211(5):961–974. doi:10.1084/jem.20131556.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989–2003. doi:10.1084/jem.20101158.
   PubMed Web of Science ®Google Scholar
• Ajina A, Maher J. Prospects for combined use of oncolytic viruses and CAR T-cells. j Immunotherapy Cancer. 2017;5(1):1–27. doi:10.1186/s40425-017-0294-6.
   PubMedGoogle Scholar
• Huang J, Zheng M, Zhang Z, et al. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother. 2021;70(9):2453–2465. doi:10.1007/s00262-021-02856-0.
   PubMed Web of Science ®Google Scholar
• Kim G, Ko YT. Small molecule tyrosine kinase inhibitors in glioblastoma. Arch Pharm Res. 2020;43(4):385–394. doi:10.1007/s12272-020-01232-3.
   PubMed Web of Science ®Google Scholar
• Wu X, Luo H, Shi B, et al. Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma. Mol Ther. 2019;27(8):1483–1494. doi:10.1016/j.ymthe.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Li H, Ding J, Lu M, et al. CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models. J Immunother. 2020;43(1):16–28. doi:10.1097/CJI.0000000000000301.
   PubMed Web of Science ®Google Scholar
• Cui J, Wang H, Medina R, et al. Inhibition of PP2A with LB-100 enhances efficacy of CAR-T cell therapy against glioblastoma. Cancers. 2020;12(1):139. doi:10.3390/cancers12010139.
   Web of Science ®Google Scholar
• Yaghoubi SS, Jensen MC, Satyamurthy N, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 2009;6(1):53–58. doi:10.1038/ncponc1278.
   PubMedGoogle Scholar
• Choi B, Suryadevara C, Gedeon P, et al. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci. 2014;21(1):189–190. doi:10.1016/j.jocn.2013.03.012.
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu Y, Huang Z, et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat Biomed Eng. 2021;5(11):1336–1347. doi:10.1038/s41551-021-00779-w.
   PubMed Web of Science ®Google Scholar
• Ravanpay AC, Gust J, Johnson AJ, et al. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget. 2019;10(66):7080–7095. doi:10.18632/oncotarget.27389.
   PubMedGoogle Scholar
• Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich P-Y, Walker PR. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol. 2007;179(2):845–853. doi:10.4049/jimmunol.179.2.845.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wei W, Wang P, et al. Biomimetic magnetosomes as versatile artificial antigen-presenting cells to potentiate T-cell-based anticancer therapy. ACS Nano. 2017;11(11):10724–10732. doi:10.1021/acsnano.7b04955.
   PubMed Web of Science ®Google Scholar
• Chen Q, Hu Q, Dukhovlinova E, et al. Photothermal therapy: Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells (Adv. Mater. 23/2019). Adv Mater. 2019;31(23):1970166. doi:10.1002/adma.201970166.
   Web of Science ®Google Scholar
• Cano-Mejia J, Burga RA, Sweeney EE, et al. Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine. 2017;13(2):771–781. doi:10.1016/j.nano.2016.10.015.
   PubMed Web of Science ®Google Scholar
• Ma W, Zhu D, Li J, et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics. 2020;10(3):1281–1295. doi:10.7150/thno.40291.
   PubMed Web of Science ®Google Scholar
• Galstyan A, Markman JL, Shatalova ES, et al. Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019;10(1):3850. doi:10.1038/s41467-019-11719-3.
   PubMed Web of Science ®Google Scholar
• Krenciute G, Prinzing BL, Yi Z, et al. Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5(7):571–581. doi:10.1158/2326-6066.CIR-16-0376.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105. doi:10.1038/mtna.2013.32.
   PubMedGoogle Scholar
• Sentman CL, Meehan KR. NKG2D CARs as cell therapy for cancer. Cancer J. 2014;20(2):156–159. doi:10.1097/PPO.0000000000000029.
   PubMed Web of Science ®Google Scholar
• Davies DM, Foster J, Van Der Stegen SJ, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med. 2012;18(4):565–576. doi:10.2119/molmed.2011.00493.
   PubMed Web of Science ®Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036–3052. doi:10.1172/JCI83416.
   PubMed Web of Science ®Google Scholar
• Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16(11):1767–1773. doi:10.7150/ijbs.41105.
   PubMed Web of Science ®Google Scholar
• Bielamowicz K, Fousek K, Byrd TT, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018;20(4):506–518. doi:10.1093/neuonc/nox182.
   PubMed Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, et al. Abstract LB-066: BiTE-armored CARs overcome antigen escape in EGFRvIII-targeted therapy for glioblastoma. AACR. 2019;79(13_Supplement):LB-066–LB-066. doi:10.1158/1538-7445.AM2019-LB-066.
   Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–2554. doi:10.1056/NEJMoa1708566.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood J Am Soc Hematol. 2014;124(2):188–195. doi:10.1182/blood-2014-05-552729.
   Google Scholar
• Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. doi:10.1038/mto.2016.11.
   PubMed Web of Science ®Google Scholar
• Mackall CL, Miklos DB. CNS endothelial cell activation emerges as a driver of CAR T cell–associated neurotoxicity. Cancer Discov. 2017;7(12):1371–1373. doi:10.1158/2159-8290.CD-17-1084.
   PubMed Web of Science ®Google Scholar
• Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6(1):4–10. doi:10.1186/s40364-018-0116-0.
   PubMedGoogle Scholar
• Liu X, Jiang S, Fang C, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75(17):3596–3607. doi:10.1158/0008-5472.CAN-15-0159.
   PubMed Web of Science ®Google Scholar
• Salter AI, Ivey RG, Kennedy JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11(544):eaat6753. doi:10.1126/scisignal.aat6753.
   PubMed Web of Science ®Google Scholar
• Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood J Am Soc Hematol. 2019;133(7):697–709. doi:10.1182/blood-2018-10-881722.
   Google Scholar
• Giavridis T, van der Stegen SJ, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–738. doi:10.1038/s41591-018-0041-7.
   PubMed Web of Science ®Google Scholar
• Staedtke V, Bai R-Y, Kim K, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018;564(7735):273–277. doi:10.1038/s41586-018-0774-y.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–167. doi:10.1038/s41571-019-0297-y.
   PubMed Web of Science ®Google Scholar
• Sommermeyer D, Hill T, Shamah SM, et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia. 2017;31(10):2191–2199. doi:10.1038/leu.2017.57.
   PubMed Web of Science ®Google Scholar
• Jonnalagadda M, Mardiros A, Urak R, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther. 2015;23(4):757–768. doi:10.1038/mt.2014.208.
   PubMed Web of Science ®Google Scholar
• Stavrou M, Philip B, Traynor-White C, et al. A rapamycin-activated caspase 9-based suicide gene. Mol Ther. 2018;26(5):1266–1276. doi:10.1016/j.ymthe.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Paszkiewicz PJ, Fräßle SP, Srivastava S, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016;126(11):4262–4272. doi:10.1172/JCI84813.
   PubMed Web of Science ®Google Scholar
• Kao RL, Truscott LC, Chiou T-T, Tsai W, Wu AM, De Oliveira SN. A cetuximab-mediated suicide system in chimeric antigen receptor–modified hematopoietic stem cells for cancer therapy. Hum Gene Ther. 2019;30(4):413–428. doi:10.1089/hum.2018.180.
   PubMed Web of Science ®Google Scholar
• Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood J Am Soc Hematol. 2013;122(20):3461–3472. doi:10.1182/blood-2013-04-493361.
   Google Scholar
• Choe JH, Watchmaker PB, Simic MS, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378. doi:10.1126/scitranslmed.abe7378.
   PubMed Web of Science ®Google Scholar
• Cornetta K, Duffy L, Turtle CJ, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. Mol Ther. 2018;26(1):280–288. doi:10.1016/j.ymthe.2017.09.008.
   PubMed Web of Science ®Google Scholar
• Marcucci KT, Jadlowsky JK, Hwang W-T, et al. Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients. Mol Ther. 2018;26(1):269–279. doi:10.1016/j.ymthe.2017.10.012.
   PubMed Web of Science ®Google Scholar
• Bear AS, Morgan RA, Cornetta K, et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012;20(2):246–249. doi:10.1038/mt.2011.288.
   PubMed Web of Science ®Google Scholar
• Morita D, Nishio N, Saito S, et al. Enhanced expression of anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells. Mol Ther Methods Clin Dev. 2018;8:131–140. doi:10.1016/j.omtm.2017.12.003.
   PubMed Web of Science ®Google Scholar
• Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD 19. Immunol Rev. 2014;257(1):181–190. doi:10.1111/imr.12137.
   PubMed Web of Science ®Google Scholar
• Bailey SR, Maus MV. Gene editing for immune cell therapies. Nat Biotechnol. 2019;37(12):1425–1434. doi:10.1038/s41587-019-0137-8.
   PubMed Web of Science ®Google Scholar
• Roth TL, Puig-Saus C, Yu R, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559(7714):405–409. doi:10.1038/s41586-018-0326-5.
   PubMed Web of Science ®Google Scholar
• Hale M, Mesojednik T, Ibarra GSR, et al. Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol Ther. 2017;25(3):570–579. doi:10.1016/j.ymthe.2016.12.023.
   PubMed Web of Science ®Google Scholar